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Abstract
The Human papillomavirus plays an important role in the initiation and progression of cervical
cancer. However, it is a necessary but not sufficient cause to develop invasive carcinoma; hence,
other factors are required in the pathogenesis of this malignancy. In this review we explore the
hypothesis of the deregulation of wnt/β-catenin signaling pathway as a "second hit" required to
develop cervical cancer.
Background
HPV and cervical cancer
Cervical carcinoma (CC) is one of the most common can-
cers and a leading cause of death among women world-
wide. [1]. The number of patients who died from this
disease in 2000 was estimated at >200,000 [2]. An impor-
tant percentage of cases occur in the developing world,
where in some countries CC is the main cause of death in
reproductive-aged and economically active women with
limited access to early diagnosis or effective treatment [1].
Over 30 years ago, some authors pointed out that CC had
sexually transmitted disease behavior [3], while others
hypothesized and analyzed a possible role of the human
papillomavirus (HPV) in this neoplasia [4,5]. But it was
until November 1991 that the association between HPV
infection and CC was officially established, after consider-
ing the epidemiologic and molecular evidence that the
DNA of HPV is integrated in more than 99% of cervical
carcinoma specimens [6,7].
At present, more than 100 types of HPV have been identi-
fied [8], 40 of which infect the genital epithelia. Genital
HPVs are classified in three groups according to their
potential to induce cervical lesions: high-risk, probable
high-risk and low-risk types [9]. Between high-risk viral
types, 16 and 18 HPV types are the most frequent viral
types, with nearly one half of all cervical cancers the
former, and 15%, the latter [9]. Fortunately, not all
patients infected with oncogenic HPVs will develop CC
due to frequent spontaneous clearance of viral sequences.
This discrepancy indicates that the majority of HPV infec-
tions are sub-clinical; therefore, only a small number of
oncogenic HPV infections will produce early epithelial
lesions, and only a very small number of these lesions will
lead to CC [10,11]. Hence, infection with high-risk HPV is
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a necessary – but not sufficient – cause for developing cer-
vical carcinoma; thus, other types of factors such as cellu-
lar, immunological, genetic, epigenetic, environmental,
etc. can affect the final outcome of the disease. In this con-
text, viral factors have been reasonably explored, produc-
ing adequate evidence to postulate the occurrence of three
events during HPV course infection as cancer promoters:
viral DNA integration to host genome; expression of viral
oncoproteins E6 and E7, and finally the complex interac-
tions between E6/E7 and cellular proteins. In this carcino-
genesis complex model, identification of viral, host, and
environmental factors exerting an influence on the risk of
disease progression from early cervical abnormalities to
invasive cancer will lead us to better knowledge of the nat-
ural history of HPV infection.
Once HPV has infected basal cells, the viral genome is rep-
licated actively as episome and early genes (E1–E7) are
expressed. E1 and E2 are important proteins for viral
genome replication and viral cycle completion [12]. E1
plays an important role in the maintenance of the viral
genome as episome [13]. In turn, E2 is involved in the
negative regulation of the transcriptional activity of viral
oncogenes E6 and E7 [14]. However, E5, E6, and E7 are
required to increase basal-cell proliferation leading to an
increase of the viral genome replication rate; therefore, a
limited expression of these genes can take place during
early stages of infection [15]. Late genes (L1 and L2)
encode viral capsid proteins and are expressed during the
late stages of virion assembly in middle and upper epithe-
lium layers. Finally, virions are encapsidated and shed
into the genital tract [16] where they can infect other areas
of epithelia or be sexually transmitted (Figure 1).
An important step during HPV infection corresponds to
viral integration into the host genome. The HPV genome
is usually replicated as episome or extrachromosomic
molecule in benign cervical precursor lesions. Cancer tis-
sues can contain both episomal and integrated HPV DNA
[17]. Because the HPV genome is a ring molecule, it
requires being open in order to be integrated; this process
often breaks the E1–E2 open reading frames. Part of E2
and adjacent regions to E2–E4, E5, and L2 are commonly
deleted after integration; therefore, the partial transcrip-
tional repression exerted by E2 is lost and viral oncogenes
E6 and E7 are actively expressed in CC tissues [18]. Fur-
thermore, viral integration frequently occurs in chromo-
somic regions where genes involved in tumorogenesis,
such as MYC, NR4A2, hTERT, APM-1, FANCC, and
TNFAIP2, etc., are found [19].
E6 and E7 epithelial expression and its interactions with
cellular proteins have been at the center of the HPV bio-
medical research scenario probably for the past 20 years.
The central core of the classic E6/E7 model is the binding
and inactivation of tumor suppressor proteins p53 and
pRb respectively; which was established between the late
1980s and the early 1990s [20,21]. Currently, it is well-
known that E6 and E7 interact with a plethora of cellular
proteins that participate in molecular pathways involved
in the activation and establishment of the malignant phe-
notype.
One of the candidate signaling pathways that has been
recently studied in cervical carcinoma model is the Wnt/
beta catenin pathway. The role of wnt signaling in cancer
was initially described 20 years ago with the seminal dis-
covery of wnt-1 gene as an integration site for mouse
mammary tumor virus (MMTV) [22]. Since then a wealth
of information has highlighted the role of the wnt path-
way in the control of several biological processes, for
instance, cell fate specification, proliferation, migration,
cell adhesion, cell polarity, tissue architecture, and orga-
nogenesis [23,24]. In an adult body, Wnts regulate hemat-
opoiesis, osteogenesis, angiogenesis, and adipogenesis
[25-27]. This wide range of biological effects shows a high
pleiotropism of wnt signals, which are also involved in
human diseases including cancer. Several reports have
demonstrated aberrant activation of the wnt signaling
pathway in different human cancers, including colorectal
[28]; gastric [29] and melanoma [30]. In CC little is
known about the wnt signaling pathway, however we and
other researchers have recently described alterations on
this pathway in cervical neoplasia. The aim of this review
therefore, is to analyze current evidence of wnt pathway
involvement on CC.
Wnt/beta-catenin signaling pathway
Wnt binds to seven-transmembrane domain proteins
denominated Frizzled (FZD). The broad range of cellular
processes regulated by the wnt pathway can be explained
-at least in part-by the high diversity between wnt proteins
and FZD receptors. In the human genome, 19 WNT and
11 FZD genes have been identified. For a complete list of
WNT and FZD genes, please visit the World Wide Web
Wnt Homepage [31]. Interactions between Wnt proteins
and their receptors show an important rate of promiscuity
[32]; therefore, a Wnt protein can bind with different FZD
receptors, and vice versa. This interaction requires the
cooperation of LRP5 and LRP6, which are long single-pass
transmembrane proteins acting as co-receptors [33].
Mutations in both genes can lead to developmental
defects similar to inactivating mutations in individual
Wnt genes, e.g., defects in dorsal thalamic development,
skeletal and neural tube abnormalities, decrease in oste-
oblast proliferation, osteopenia, and persistent embry-
onic eye vascularization [34-36]. This evidence shows that
LRPs proteins perform an important role in Wnt pathway
activation and regulation. The interaction between LRP5/
6, FZD, and Wnt can be regulated by secreted proteinsInternational Archives of Medicine 2008, 1:10 http://www.intarchmed.com/content/1/1/10
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such as Dikkopf (Dkk), secreted frizzled-related proteins
(sFRP), and Cerberus1 (Cer1), which can inhibit wnt sig-
naling through direct binding to wnt or co-receptor mole-
cules. Dkk binds to LRP with other transmembrane
proteins, the Kremens (Krm); thus promoting LRP inter-
nalization and inactivation [37,38]
Currently there are three well-known pathways that are
activated after Wnt couples with its receptors. The path-
way which is activated depends on the specificity of the
Wnt ligand and its FZD receptor and surely on cellular
components such as co-activators or co-repressors that
exert a fine-tune regulation. These pathways are: 1. The
canonical pathway which induces the stabilization and
entry to nucleus of β-catenin, where it affects the transcrip-
tion of target genes (figure 2) [39]. 2. The planar cell
polarity pathway (PCP) which establishes the polariza-
tion of cells within the plane of a cell sheet. This pathway
is important during neural tube closure and cochlear
extension [40]. And finally, 3. The Wnt/Ca+2 or "non-
canonical pathway", which regulates cell adhesion and
motility mediated by the Wnt-5a, triggers intracellular
Ca2+ release in order to activate Ca2+-sensitive enzymes
such as the protein kinase C (PKC) and Ca2+/calmodulin-
dependent kinase II (CaMKII) without the activation of
the β-catenin pathway [41]. The canonical pathway is the
best understood pathway, a hallmark of cancer and a cen-
tral topic in this review.
Following the trimerization of Wnt/Fzd/LRPs, the LRP co-
receptor is phosphorylated leading to the binding and
phosphorylation of Disheveled (Dvl), which transduces
the Wnt signal into the cell through direct binding with
FZD [42,43]. Dvl is a central player in the Wnt signal rout-
ing and amplification through pathway-specific effectors
[44]. Dvl interacts with axin, which performs a scaffolding
function in the wnt pathway by its association with key
proteins for β-catenin phosphorylation and poly-ubiqui-
tination, including GSK-3β, CK1, APC, and β-catenin
itself. The consequence of axin phosphorylation is β-cat-
enin activation through axin sequestration and its inacti-
vation by the proteasome pathway. Some reports indicate
that in mammalian cell culture wnt activation precedes
axin degradation, however, the exact mechanism remains
unclear [45].
An important hallmark in the canonical Wnt pathway is
the stabilization of β-catenin in cytoplasm and its accu-
mulation into the nucleus. This is possible due to the
detachment of β-catenin from the degradation complex, a
multi-protein assembly activated in the absence of wnt
signaling, whose main task is to add ubiquitins to β-cat-
enin resulting in its inactivation by means of the ubiqui-
tin-proteasome pathway [24]. In an unstimulated cell, β-
catenin interacts with E-cadherin and α-catenin at epithe-
lial cell adherens junctions, regulating cell adhesion. The
excess of β-catenin levels are modulated by means of the
degradation complex [46]. A key component of the degra-
dation complex is APC. When β-catenin binds to APC, it
displaces the union of axin because the binding affinity of
β-catenin increases dramatically upon phosphorylation
and because the binding motifs of APC to axin and β-cat-
enin overlap [47]. Most colorectal tumors contain truncat-
ing mutations on APC, which leads to an inability to bind
Axin or degrade β-catenin [48].
After the FZ/LRP activation by its ligand, the degradation
complex kinase activity is inhibited. Consequently, non-
phosphorylated β-catenin is stabilized, and increasing lev-
els tend to accumulate in the cytoplasm. β-catenin accu-
mulation in cytoplasm leads to its nuclear accumulation,
HPV viral cycle and cervical cancer development Figure 1
HPV viral cycle and cervical cancer development. 
Human papillomavirus (HPV) gains access to basal cells 
through microabrassions or by infecting the transformation 
zone, an abrupt transition from a columnar to a squamous 
epithelium. Infected cells actively express the early genes E1, 
E2, E4 and E5. Viral oncoproteins E6 and E7 are expressed in 
limited amounts due to transcriptional repression exerted by 
E2. Infected basal cells migrate to the lumen as they differen-
tiate; differentiated epithelial cells express the late capside 
genes L1 and L2. In subclinical infections or low grade intra-
epithelial-lesions (LGSIL) the viral genome replicates as an 
episome and is encapsidated in the nucleus of the upper layer 
epithelium cells. Shed viral particles then can infect new 
zones of epithelium or be sexually transmitted. Only a lim-
ited number of infections progress to high grade intra-epithe-
lial-lesions (HGSIL) and cervical carcinoma (CC). The 
progression of LGSIL to CC is associated with the integra-
tion of the HPV genome into the host genome and the loss 
of transcriptional repression exerted by E2.International Archives of Medicine 2008, 1:10 http://www.intarchmed.com/content/1/1/10
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where it is associated with lymphoid enhancer-binding
factor 1/Tcell-specific transcription factor (LEF/TCF) and
transcriptional activator Pygopus (Pygo). Pygo contains a
domain (PHD), which is shared by many nuclear proteins
with a role in chromatin remodeling and transcriptional
co-activation [49]. Mutations in Pygo result in many
defects that are very similar to those of wnt loss-of-func-
tion [50].
In the absence of wnt signaling, TCF is bound to Groucho,
forming a repressor complex of Wnt target genes. Groucho
can repress gene transcription by inhibition of basal tran-
scriptional machinery and recruitment of histone deacety-
lases (HDACs) [51,52]. Although Groucho does not
interact with DNA, it exerts its repressive function by its
interaction with the tails of core histones H3 and H4 and
by modifying chromatin structure [53]. Thus, the specifi-
city of the genes that will be repressed by Groucho is pro-
vided by LEF/TCF.
When β-catenin enters the nucleus, it converts the repres-
sor LEF/TCF/Groucho into a transcriptional activator
complex. This is possible due to Groucho displacement by
interaction between β-catenin and LEF/TCF, thereby acti-
vating wnt target genes [54]. Several genes activated by the
wnt signaling pathway, which are mainly involved in cell
proliferation and differentiation processes, have been
identified; for a comprehensive list of genes regulated by
this signaling pathway, please visit the Wnt homepage.
Wnt pathway and cervical carcinoma
To this point we have reviewed how the wnt/β-catenin
pathway turns on complex signaling events leading to the
activation of target genes. Mutations in several compo-
nents of this pathway have been studied and identified in
nearly all human cancers. However, in cervical cancer only
few studies have shown the involvement of certain wnt/β-
catenin genes in their pathogenesis. In this regard, it has
been suggested that HPV-immortalized human keratinoc-
yte transformation requires a second hit and could be
achieved thanks to the activation of the canonical wnt
Wnt canonical signaling pathway Figure 2
Wnt canonical signaling pathway. A. When the wnt signaling pathway is not active, β-catenin is bound to the degradation 
complex composed by APC, axin, and the serine/theronine kinases CK1 and GSK3. The main role of the degradation complex 
is to phosphorylate β-catenin leading to its degradation by means of the proteasome-ubiquitin pathway. There are several neg-
ative regulators that operate at the receptor-ligand level; such as, Cer1, DKK, WIF1 and sFRP, whose function is to modulate 
positive signals induced by Wnts. B. The contact of wnt with its receptors leads to the stabilization of β-catenin and its accumu-
lation in cytoplasm and nucleus. β-catenin displaces the transcriptional repressor groucho from the LEF/TCF complex, leading 
to the activation of target genes, such as c-myc and cyclinD1, which are involved in cell proliferation and cell cycle progression.International Archives of Medicine 2008, 1:10 http://www.intarchmed.com/content/1/1/10
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pathway [55]. This hypothesis is supported by the fact that
β-catenin expression is increased in 73% of CC speci-
mens, with cytoplasmic and nuclear positive staining,
nevertheless mutations were found in only 20% of the
analyzed cases [56]. Thus, evidence suggests the activation
of β-catenin at an upstream level, which can be accom-
plished by the inactivation of negative regulators such as
APC and axin. It is well-known that during carcinogenesis,
distinct tumor suppressor genes are inactivated by abnor-
mal methylation of CpG islands, probably by means of an
increase in DNA methyltransferase (DNMT) activity [57].
HPV16/E7 has the capacity to bind and increase the dna
methyl transferase enzyme (DNMT1) activity, the enzyme
responsible to add methyl groups on CpG islands [58];
thus, it is feasible that negative wnt/β catenin-pathway
regulators could be inactivated by methylation. In this
respect, sFRPs, axin, DICKKOPF (Dkk) and APC genes
have enriched CpG islands in their promoters which can
be found as hypermethylated in some neoplasias includ-
ing CC [29,59-61]; therefore, it is probable that these
genes could be inactivated by promoter methylation dur-
ing cervical carcinogenesis.
Another mechanism involved in the upstream activation
of the wnt/β-catenin pathway is over-expression of path-
way activators such as wnt ligands, frizzled receptors, and
disheveled. There is evidence showing over-expression of
WNT10B, -14, FZD10, and DVL-1 in cervical cell lines [62-
65]; nonetheless, this has not been explored in patholog-
ical specimens by traditional single-gene methodologies
such as RT-PCR, immunohistochemistry, or Western and
Northern blot.
We recently conducted a genome-wide expression analy-
sis in HPV16 CC compared against normal cervix epithe-
lia [66]. We were able to identify genes and cellular
pathways with aberrant expression levels, and one of the
most altered pathways was wnt/β-catenin. In this work,
we analyzed the expression levels of 55,000 sequences
that virtually represent all genes expressed in the human
genome. In this way, we showed a significant increment of
Wnt4, -8a, Fzd2, GSK3β, and β-catenin in tumors . In
addition, genes also belonging to this pathway are actively
expressed in normal cervical epithelia, such as sFRP4,
PPP2C, and FZD7 (Figure 3). This evidence demonstrates
two important facts: First, deregulation in specific genes
belonging to wnt/β-catenin pathway could play an impor-
tant role in cervical carcinogenesis, and second, the pres-
ence of some wnt/β-catenin-related genes in normal
tissues suggests that this pathway is involved in cervical
epithelial differentiation. Additionally, it is noteworthy
that sFRP4, a negative regulator of wnt that inhibits recep-
tor activation by competition with wnt proteins, is
actively expressed in normal epithelia and absent in CC
tissues, which indicates that this gene could be important
in balancing the positive signals leading to the binding of
wnt to its receptor, hence regulating overactivation in wnt-
induced cell signaling.
Interestingly, gene components of the planar cell polarity
(PCP) pathway were actively expressed in normal cervices,
showing that this branch of wnt signaling is downregu-
lated in CC (Figure 3). In vertebrates, PCP is considered as
any process affecting cell polarity within an epithelial
plane and involving one or more core PCP genes. PCP has
shown to be an important developmental and adult tissue
differentiation process. At present, the developmental
processes that meet these criteria include convergent
extension, neural tube closure, eyelid closure, hair bundle
orientation in inner ear sensory cells, and hair follicle ori-
entation in the skin [67]. To our knowledge, there are no
previous reports showing active PCP genes in normal cer-
vical epithelia. This result demonstrates that during the
carcinogenesis process, infected cervical cells turn off the
PCP pathway, activating the canonical pathway with an
increase of genes participating in it, e.g., Wnt4, -8A, FZD2,
CTNNB1, among others. This turning-on of the canonical
pathway leads to the activation of target genes such as
MYC, JUN, FOS, and RRAS (for a complete list of altered
genes in HPV16CC, please see the additional file 2 in
[66]). A possible mechanism explaining how the canoni-
cal pathway is privileged in HPV16CC might be sFRP4
inactivation in normal cells. In an unpublished work, we
observe that sFRP4 and DKK are inactivated by promoter
methylation in CC; when cells are treated with DNMTs
inhibitors we detect a re-expression of these genes
(unpublished data). It has been shown that the sFRP gene
is frequently inactivated by promoter methylation in gas-
tric and hepatocellular cancer (HCC) [29,68]. Moreover,
sFRP1 restoration attenuated Wnt signaling in HCC cells,
decreased abnormal beta-catenin accumulation in
nucleus and suppressed cell growth [68]. As previously
described, it is common to find cytoplasmic and nuclear
β-catenin accumulation in CC accompanied by occasional
mutations in the CTNNB gene. With the previous evi-
dence; we could speculate that canonical-pathway activa-
tion in CC is accomplished by means of inactivation of
wnt negative regulators such as sFRP genes, and particu-
larly SFRP4 and Dkk, as we were able to show [66,69].
Concluding remarks
Even though the extensive use of the Papanicolau smear
and colposcopy examination have significantly decreased
the mortality rates, CC remains as the second cause of
death in women worldwide. HPV sequences have been
found in more than 99% of CC and HPV infection is the
most important etiologic factor in cervical carcinogenesis.
Besides, HPV infection is very common among the young
sexually active population, but only a small fraction of
infected individuals will develop cervical carcinoma laterInternational Archives of Medicine 2008, 1:10 http://www.intarchmed.com/content/1/1/10
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in life. Thus, HPV can be considered as an initial hit in the
multistep carcinogenesis that leads to the development of
CC. The molecular pathways involved in the progression
of HPV-infected cells to CC have not yet been accurately
identified. Here, we reviewed the role of Wnt/β-catenin
pathway activation and the inactivation of planar cell
polarity pathway in CC cells as a second hit to develop
CC.
In CC mutations on CTNNB1 gene are uncommon; thus
the activation on wnt signalling pathway it seems to be
activated upstream of/β-catenin. This fact could be
achieved by means of negative regulators inactivation or
over-expression of pathway activators.
Other branch in wnt signaling pathway that could be rel-
evant during CC pathogenesis is planar cell polarity (PCP)
pathway, which is involved in differentiation processes.
PCP is a key differentiation and morphogenetic process
involved in development of epithelia. In normal cervical
epithelia, cells are polarized and migrate from basal to the
luminal space as they differentiate. Interestingly, PCP
component genes are down-expressed in CC, indicating
that this mechanism could be abated prior the establish-
ment of the neoplasia. From the diagnostic point of view
this fact could be important, because if we were able to
show as an early process, we could account with potential
molecular markers for early detection.
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Wnt signaling pathwhay in cervical cancer Figure 3
Wnt signaling pathwhay in cervical cancer. Expression levels of some genes participating in the wnt/β-catenin signaling 
pathway are altered in CC. Interestingly, Planar Cell Polarity pathway (PCP) is present in normal epithelial cells but is down-
regulated in CC. A possible mechanism to accomplish PCP down-regulation is the inactivation of sFRP transcription. Yellow 
boxes indicate a down-regulation of expression in tumor cervices' samples compared to normal cervices' samples. Red boxes 
indicate a higher gene expression in cervical carcinoma samples. Blue boxes show that a member of the indicated gene family is 
expressed in normal tissues, and another member of the same family in tumors. Green boxes indicate that the gene was not 
altered. Figure modified from Infect Agent Cancer. 2007; 2: 16.
Planar Planar Cell Cell Polarity Polarity
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